525 related articles for article (PubMed ID: 25681534)
1. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
[TBL] [Abstract][Full Text] [Related]
2. PET imaging with [
Tang J; Xu Y; Liu C; Fang Y; Cao S; Zhao C; Huang H; Zou M; Chen Z
Nucl Med Biol; 2020; 90-91():1-9. PubMed ID: 32861175
[TBL] [Abstract][Full Text] [Related]
3. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD.
Sossi V; Holden JE; Topping GJ; Camborde ML; Kornelsen RA; McCormick SE; Greene J; Studenov AR; Ruth TJ; Doudet DJ
J Cereb Blood Flow Metab; 2007 Jul; 27(7):1407-15. PubMed ID: 17245418
[TBL] [Abstract][Full Text] [Related]
4. In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of Parkinson disease using 11C-methylphenidate PET.
Sossi V; Dinelle K; Jivan S; Fischer K; Holden JE; Doudet D
J Nucl Med; 2012 May; 53(5):813-22. PubMed ID: 22492730
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease.
Casteels C; Lauwers E; Bormans G; Baekelandt V; Van Laere K
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):124-34. PubMed ID: 17906859
[TBL] [Abstract][Full Text] [Related]
7. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET.
Fischer K; Sossi V; von Ameln-Mayerhofer A; Reischl G; Pichler BJ
Neuroimage; 2012 Feb; 59(3):2413-22. PubMed ID: 21945469
[TBL] [Abstract][Full Text] [Related]
8. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Frau L; Morelli M; Simola N
Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
[TBL] [Abstract][Full Text] [Related]
9. Place conditioning to apomorphine in rat models of Parkinson's disease: differences by dose and side-effect expression.
Campbell JC; Jeyamohan SB; De La Cruz P; Chen N; Shin D; Pilitsis JG
Behav Brain Res; 2014 Dec; 275():114-9. PubMed ID: 25205367
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.
Zhu A; Wang X; Yu M; Wang JQ; Brownell AL
J Cereb Blood Flow Metab; 2007 Sep; 27(9):1623-31. PubMed ID: 17299451
[TBL] [Abstract][Full Text] [Related]
11. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
12. EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease.
Vorobyov VV; Schibaev NV; Morelli M; Carta AR
Brain Res; 2003 May; 972(1-2):177-85. PubMed ID: 12711091
[TBL] [Abstract][Full Text] [Related]
13. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET.
Nikolaus S; Larisch R; Beu M; Forutan F; Vosberg H; Müller-Gärtner HW
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):390-5. PubMed ID: 12634967
[TBL] [Abstract][Full Text] [Related]
14. Characterization of gray matter atrophy following 6-hydroxydopamine lesion of the nigrostriatal system.
Westphal R; Sumiyoshi A; Simmons C; Mesquita M; Wood TC; Williams SC; Vernon AC; Cash D
Neuroscience; 2016 Oct; 334():166-179. PubMed ID: 27506141
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
16. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
17. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats.
Inaji M; Okauchi T; Ando K; Maeda J; Nagai Y; Yoshizaki T; Okano H; Nariai T; Ohno K; Obayashi S; Higuchi M; Suhara T
Brain Res; 2005 Dec; 1064(1-2):136-45. PubMed ID: 16298352
[TBL] [Abstract][Full Text] [Related]
18. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 10-(11) C-dihydrotetrabenazine as a vesicular monoamine transporter 2 radioligand.
Li X; Chen Z; Tang J; Liu C; Zou P; Huang H; Tan C; Yu H
Arch Pharm (Weinheim); 2014 May; 347(5):313-9. PubMed ID: 24497196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
